Synaptic Vesicle Cycle

Synaptic Vesicle Cycle

Overview

The synaptic vesicle cycle is the fundamental process by which neurotransmitters are packaged, transported, released, and recycled at presynaptic terminals. This cycle is essential for neurotransmission and involves coordinated interactions between hundreds of proteins that ensure precise temporal control of neurotransmitter release.

The Complete Synaptic Vesicle Cycle

Stage 1: Vesicle Biogenesis and Acidification

Synaptic Vesicle Formation

Synaptic vesicles are generated from the Golgi apparatus and pre-synaptic plasma membrane through a process involving:

• Clathrin-mediated budding from endosomes
• Phosphatidylinositol metabolism (PI(4,5)P₂, PI(3,4,5)P₃)
• Dynamin GTPase for membrane scission

V-ATPase and Acidification

The vacuolar-type H⁺-ATPase (V-ATPase) pumps protons into the vesicle lumen, creating:

• Electrochemical gradient (ΔpH ≈ 0.6)
• Membrane potential (Δψ ≈ 40 mV)
• Driving force for neurotransmitter uptake

Stage 2: Neurotransmitter Loading

Vesicular Transporters

Different neurotransmitters use specific vesicular transporters:

...

Synaptic Vesicle Cycle

Overview

The synaptic vesicle cycle is the fundamental process by which neurotransmitters are packaged, transported, released, and recycled at presynaptic terminals. This cycle is essential for neurotransmission and involves coordinated interactions between hundreds of proteins that ensure precise temporal control of neurotransmitter release.

The Complete Synaptic Vesicle Cycle

Stage 1: Vesicle Biogenesis and Acidification

Synaptic Vesicle Formation

Synaptic vesicles are generated from the Golgi apparatus and pre-synaptic plasma membrane through a process involving:

• Clathrin-mediated budding from endosomes
• Phosphatidylinositol metabolism (PI(4,5)P₂, PI(3,4,5)P₃)
• Dynamin GTPase for membrane scission

V-ATPase and Acidification

The vacuolar-type H⁺-ATPase (V-ATPase) pumps protons into the vesicle lumen, creating:

• Electrochemical gradient (ΔpH ≈ 0.6)
• Membrane potential (Δψ ≈ 40 mV)
• Driving force for neurotransmitter uptake

Stage 2: Neurotransmitter Loading

Vesicular Transporters

Different neurotransmitters use specific vesicular transporters:

| Transporter | Gene | Neurotransmitter | Location |
|-------------|------|-----------------|----------|
| VGLUT1 | SLC17A6 | Glutamate | Excitatory neurons |
| VGLUT2 | SLC17A6 | Glutamate | Thalamus, brainstem |
| VGLUT3 | SLC17A7 | Glutamate | Monoamine neurons |
| VMAT2 | SLC18A2 | Dopamine, Serotonin, Norepinephrine | Aminergic neurons |
| VIAAT | SLC32A1 | GABA, Glycine | Inhibitory neurons |
| VAChT | SLC18A3 | Acetylcholine | Cholinergic neurons |

Loading Mechanism

• Secondary active transport: Transporters use the H⁺ gradient
• Exchange: 2 H⁺ exchanged per neurotransmitter molecule
• Stoichiometry: ~10,000 neurotransmitters per vesicle (glutamate)

Stage 3: Vesicle Transport and Docking

Active Zone Architecture

The active zone is a specialized presynaptic structure containing:

• RIM proteins (RIM1, RIM2): Recruiting Ca²⁺ channels
• Munc13: Priming vesicles
• Munc18: Syntaxin binding
• ELKS/CAST: Scaffold proteins
• Piccolo/Achino: Cytoskeletal anchoring

Vesicle Docking

Docking involves:

Rab effectors: Rab3-GTP interacts with RIM

t-SNARE recruitment: Syntaxin to plasma membrane

v-SNARE formation: Synaptobrevin on vesicle

Munc13-Munc18 complex: Promoting SNARE assembly

Stage 4: Priming and SNARE Complex Assembly

SNARE Complex Structure

The SNARE complex consists of:

| SNARE Protein | Type | Gene | Structure |
|---------------|------|------|-----------|
| Synaptobrevin-2 (VAMP2) | v-SNARE | VAMP2 | R-SNARE (Arg) |
| Syntaxin-1 | t-SNARE | STX1 | Q-SNARE (Gln) |
| SNAP-25 | t-SNARE | SNAP25 | Q-SNARE (Gln) × 2 |

Assembly Process

Energy Requirements

• Zippering energy: ~35 kT per SNARE complex
• Coordinating complex: Complexin, Munc13
• Inhibition: Botulinum neurotoxins cleave SNARE proteins

Stage 5: Ca²⁺-Triggered Fusion

Synaptotagmin Family

Synaptotagmin (SYT) is the primary Ca²⁺ sensor:

| Protein | Ca²⁺ Binding | Function |
|---------|--------------|----------|
| Synaptotagmin-1 | C2A, C2B domains | Fast synchronous release |
| Synaptotagmin-2 | C2A, C2B domains | Similar to SYT1 |
| Synaptotagmin-7 | C2A, C2B domains | Asynchronous release |
| Synaptotagmin-9 | C2A, C2B domains | Partial compensation |

Fusion Mechanism

Ca²⁺ entry: Through voltage-gated calcium channels (VGCC)

Synaptotagmin binding: Ca²⁺ binds C2 domains

Membrane penetration: Hydrophobic loops insert into membranes

SNARE acceleration: Synaptotagmin displaces complexin

Fusion pore opening: Hemifusion intermediate forms

Full fusion: Pore expands, vesicle collapses

Stage 6: Neurotransmitter Release

Release Quantal Properties

• Quantum: Contents of single vesicle (~10,000 molecules)
• Quantal size: Response amplitude per vesicle
• Release probability (Pᵣ): Typically 0.1-0.9
• Miniature events (mEPSPs): Spontaneous release

Kinetics

• Synchronous release: <1 ms after Ca²⁺ entry
• Asynchronous release: 10-100 ms delay
• Facilitation: Pᵣ increases with repeated stimuli
• Depression: Pᵣ decreases with high frequency

Stage 7: Endocytosis

Clathrin-Mediated Endocytosis

After fusion, vesicle membrane is retrieved through:

Coat assembly: Clathrin triskelions + adaptin (AP2)

Cargo selection: SNARE proteins as internalization signals

Membrane curvature: Amphiphysin, endophilins

Scission: Dynamin GTP hydrolysis

Uncoating: Hsc70, auxilin

Alternative Pathways

• Kiss-and-run: Fusion pore opens briefly, closes
• Bulk endocytosis: Large membrane infoldings
• Activity-dependent bulk endocytosis: During intense stimulation

Stage 8: Vesicle Recycling

Recycling Pathways

Direct reuse: Vesicle refilled without full cycle

Endosomal sorting: Via early endosomes

Local recycling: At active zone periphery

Global pool: Full pool replenishment

Re-acidification

• V-ATPase pumps restore H⁺ gradient
• Transporter reloading
• Ready for next release cycle

Key Proteins and Genes

| Protein | Gene | Function | Page |
|---------|------|----------|------|
| Synaptophysin | SYP | Major SV protein | [/proteins/synaptophysin](/proteins/synaptophysin) |
| Synaptotagmin-1 | SYT1 | Ca²⁺ sensor | (create) |
| VAMP2 | VAMP2 | v-SNARE | (create) |
| SNAP-25 | SNAP25 | t-SNARE | [/genes/snap25](/genes/snap25), [/proteins/snap25-protein](/proteins/snap25-protein) |
| Syntaxin-1 | STX1 | t-SNARE | (create) |
| Munc13-1 | UNC13B | Vesicle priming | (create) |
| Munc18-1 | STXBP1 | Syntaxin binding | [/proteins/stxbp1](/proteins/stxbp1) |
| Rab3A | RAB3A | Vesicle transport | (create) |
| Dynamin-1 | DNM1 | Membrane scission | (create) |
| Clathrin heavy chain | CLTC | Coat protein | (create) |

Regulation

Short-Term Plasticity

• Facilitation: Increased Pᵣ from residual Ca²⁺
• Depression: Vesicle pool depletion
• Augmentation: Medium-term enhancement
• Potentiation: Long-term enhancement

Long-Term Regulation

• Synaptic activity modulates protein expression
• Neuromodulators alter release probability
• Homeostatic scaling adjusts for activity changes

Disease Implications

Neurodegenerative Diseases

Dysregulation of the synaptic vesicle cycle is implicated in:

• Alzheimer's Disease: Amyloid-β disrupts SNARE complex
• Parkinson's Disease: α-Synuclein binds to vesicles
• ALS: Synaptic vesicle depletion

Therapeutic Targets

• VMAT2: L-DOPA treatment in PD
• Botulinum toxins: Therapeutic paralysis
• Calcium modulators: Altering release properties

Alzheimer's Disease and Synaptic Vesicle Dysfunction

Amyloid-β Impact on Synaptic Transmission

Alzheimer's disease (AD) represents one of the most extensively studied neurodegenerative conditions with respect to synaptic vesicle cycle disruption. Amyloid-beta (Aβ) peptides, the hallmark aggregating species in AD, directly interact with multiple components of the synaptic machinery. Research has demonstrated that Aβ oligomers bind to presynaptic terminals and impair neurotransmitter release through several mechanisms[@jack2023]:

SNARE Complex Disruption: Aβ oligomers bind to syntaxin-1 and SNAP-25, disrupting the formation and stability of the SNARE complex. This impairment reduces the efficiency of vesicle fusion and diminishes synaptic transmission. The C-terminal region of Aβ shows particular affinity for the SNARE proteins, leading to misfolding and aggregation that sequesters these critical components[@chen2019].

Synaptotagmin-1 Impairment: Aβ interferes with synaptotagmin-1's calcium-binding capacity, reducing its efficacy as a calcium sensor. This directly impacts the rapid, synchronous neurotransmitter release that is essential for proper synaptic communication.

Vesicle Pool Depletion: Chronic Aβ exposure reduces the size of the readily releasable pool (RRP) of synaptic vesicles, limiting the capacity for sustained synaptic transmission during periods of high activity.

Tau Pathology and Synaptic Vesicles

Hyperphosphorylated tau protein, forming neurofibrillary tangles in AD, also contributes to synaptic vesicle cycle dysfunction. Tau localizes to presynaptic terminals where it can:

Disrupt vesicle trafficking: Tau interferes with the molecular motors that transport vesicles along microtubules

Alter neurotransmitter release: Tau reduces the density of synaptic vesicles at the active zone

Impair vesicle recycling: Endocytosis pathways are compromised by tau pathology

Parkinson's Disease and Synaptic Vesicle Dysfunction

Alpha-Synuclein and Presynaptic Function

Parkinson's disease (PD) is intrinsically linked to synaptic vesicle dysfunction through the aggregation of alpha-synuclein (α-syn) at presynaptic terminals. α-Syn is a natively unstructured protein that under pathological conditions forms oligomers and fibrils that disrupt normal synaptic function[@calahorra2021]:

SNARE Complex Binding: α-Syn directly binds to synaptobrevin-2 (VAMP2) and other SNARE proteins. At physiological concentrations, this interaction may serve a regulatory role; however, under pathological conditions, α-syn aggregation sequesters SNARE components and impairs complex assembly[@burr2015].

Vesicle Membrane Interactions: α-Syn has high affinity for acidic phospholipids in synaptic vesicle membranes. Pathological mutations (A53T, A30P) accelerate membrane binding and promote oligomerization that disrupts vesicle integrity and function.

Dopaminergic Synaptic Specificity: In PD, substantia nigra dopaminergic neurons are particularly vulnerable due to their unique synaptic physiology:

• High basal firing rates require sustained vesicle cycling
• Reliance on precise timing of neurotransmitter release
• Limited compensatory capacity compared to other neuronal populations

Therapeutic Implications

Understanding α-syn's role in synaptic vesicle dysfunction has led to therapeutic strategies:

Small molecule inhibitors: Compounds that prevent α-syn aggregation

Immunotherapies: Antibodies targeting pathological α-syn species

Gene therapy: Approaches to modulate α-syn expression

Amyotrophic Lateral Sclerosis and Synaptic Dysfunction

ALS presents unique synaptic vesicle cycle abnormalities that contribute to motor neuron degeneration. Both familial and sporadic forms of ALS show[@kaur2022]:

Vesicle Pool Depletion: Reduced number of synaptic vesicles in motor neuron terminals Impaired Vesicle Recycling: Endocytosis defects limit vesicle replenishment Synaptic Protein Mislocalization: SNARE proteins show abnormal distribution

The VAMP2 (synaptobrevin) protein has been implicated in ALS pathogenesis, with mutations in VAMP2 associated with neurodevelopmental disorders affecting synaptic function.

Molecular Mechanisms of Vesicle Cycle Dysregulation

Calcium Signaling Abnormalities

Calcium (Ca²⁺) dysregulation is a common feature in neurodegenerative diseases that profoundly impacts synaptic vesicle function:

Elevated Resting Calcium: Chronic elevation of basal Ca²⁺ levels in neurons leads to:

• Impaired vesicle re-acidification
• Reduced release probability
• Dysregulated synaptotagmin function

Ca²⁺ Buffering Deficits: Changes in calbindin, parvalbumin, and other calcium-binding proteins alter the kinetics of calcium signaling, affecting the precise timing of neurotransmitter release.

Mitochondrial Dysfunction and Energy Depletion

The synaptic vesicle cycle is energetically demanding, requiring:

• ATP for V-ATPase function
• ATP for vesicle transport via molecular motors
• Energy for neurotransmitter synthesis and loading

Mitochondrial dysfunction in neurodegeneration reduces ATP availability, impairing these critical processes. The high energy demands of sustained vesicle cycling make synapses particularly vulnerable to metabolic stress.

Membrane Lipid Alterations

Changes in lipid composition of synaptic membranes affect:

• Vesicle fusion efficiency
• SNARE complex dynamics
• Synaptotagmin membrane interactions

In neurodegenerative diseases, altered lipid metabolism contributes to membrane properties that impair synaptic vesicle cycle function.

Therapeutic Targets and Drug Development

Modulation of Synaptic Vesicle Proteins

Several therapeutic strategies target components of the synaptic vesicle cycle[@brenner2022]:

| Target | Strategy | Status |
|--------|----------|--------|
| Synaptotagmin-1 | Ca²⁺ binding modulators | Preclinical |
| SNARE complex | Stabilizing peptides | Preclinical |
| V-ATPase | Proton pump enhancers | Research phase |
| VMAT2 | L-DOPA/carbidopa | Approved for PD |
| VGLUT | Transporter modulators | Research phase |

Gene Therapy Approaches

Viral vector-mediated gene delivery targeting synaptic proteins:

• AAV vectors encoding wildtype SNARE components
• siRNA approaches to reduce pathological protein expression
• CRISPR-based editing of disease-causing mutations

Small Molecule Modulators

Synaptotagmin Modulators: Compounds that enhance synaptotagmin's calcium sensitivity SNARE Stabilizers: Small molecules that promote SNARE complex assembly Vesicle Cycle Enhancers: Drugs that improve vesicle recycling kinetics

Measurement Techniques and Biomarkers

Electrophysiological Approaches

• Patch clamp recordings: Measure postsynaptic responses
• Miniature EPSC/IPSC analysis: Quantal properties
• Paired-pulse facilitation: Release probability assessment

Imaging Methods

• FM dye labeling: Vesicle dynamics visualization
• Electron microscopy: Synaptic ultrastructure
• Super-resolution microscopy: Protein localization

Biochemical Markers

• CSF neurotransmitters: Levels reflect synaptic function
• Vesicle proteins in blood: Potential peripheral biomarkers
• SNARE complexes: Assembled vs. disassembled states

Future Directions

Understanding Synaptic Vulnerability

Why certain neurons are more vulnerable to synaptic vesicle cycle dysfunction remains an important question:

Neuronal subtype-specific properties: Different neurons have varying capacities for vesicle cycling

Activity-dependent stress: High firing rates increase vulnerability

Protein expression patterns: Regional differences in synaptic protein expression

Biomarker Development

Synaptic vesicle proteins as biomarkers:

• Cerebrospinal fluid SNARE complexes
• Blood-derived synaptic vesicles
• Imaging of synaptic density using PET ligands

Therapeutic Optimization

Future therapies will likely combine:

• Multiple targets within the vesicle cycle
• Disease-modifying approaches with symptomatic relief
• Personalized medicine based on genetic and biomarker profiles

Detailed Molecular Mechanisms

Synaptotagmin Family in Disease Context

The synaptotagmin family consists of at least 17 isoforms in humans, with Synaptotagmin-1 (SYT1) being the primary calcium sensor for fast synchronous neurotransmitter release. In neurodegenerative contexts[@shin2022]:

Synaptotagmin-1 in Alzheimer's Disease: Aβ oligomers directly bind to the C2B domain of SYT1, competitively inhibiting calcium binding. This leads to:

• Reduced release probability
• Impaired synchronous release
• Elevated asynchronous release

Synaptotagmin-7 in Neurodegeneration: This isoform mediates asynchronous release and has been implicated in:

• Extended time windows for neurotransmitter release
• Potential compensatory mechanisms when SYT1 is impaired
• Differential vulnerability in different brain regions

Complexin and Synaphin in Synaptic Regulation

Complexin (CPLX) and synaphin play critical regulatory roles in synaptic vesicle cycling:

Complexin Function:

• Binds to assembled SNARE complexes
• Prevents full zippering until calcium-triggered activation
• Acts as a "clamp" that maintains vesicles in a primed state

Disease Implications:

• Altered complexin levels in AD and PD
• Mutations in complexin genes associated with neurological disorders
• Therapeutic potential of complexin modulators

Endophilins and Amphiphysin in Endocytosis

The endocytic phase of the synaptic vesicle cycle relies on specialized proteins[@saheki2012]:

Endophilins:

• Promote membrane curvature
• Sense and generate curvature through amphipathic helices
• Interact with dynamin and synaptojanin

Amphiphysin:

• BAR domain proteins that shape membranes
• Coordinate clathrin coat assembly
• Link to cytoskeletal elements

In Neurodegeneration:

• Altered expression in AD and PD
• Autoantibodies in certain neurological conditions
• Potential therapeutic targets for synaptic recovery

Quantitative Aspects of Synaptic Vesicle Cycling

Vesicle Pools and Kinetics

The presynaptic terminal maintains distinct vesicle pools with different kinetic properties:

Readily Releasable Pool (RRP):

• 5-20 vesicles per terminal in central nervous system
• Rapid depletion with sustained stimulation
• Refilled through replenishment mechanisms

Reserve Pool:

• Hundreds of vesicles per terminal
• Mobilized during high-frequency stimulation
• Dependent on actin cytoskeleton dynamics

Recycling Pool:

• Approximately 10-20% of total vesicles
• Directly recycled without passing through endosomes
• Essential for sustained synaptic transmission

Energetic Requirements

Each synaptic vesicle cycle consumes significant energy:

| Process | ATP Consumption |
|---------|-----------------|
| Vesicle acidification (V-ATPase) | ~10-15 ATP per vesicle |
| Neurotransmitter loading | 2-4 ATP per molecule |
| Vesicle transport | 1-2 ATP per step |
| SNARE assembly | Energy from zippering |

Temporal Dynamics

Fast Synaptic Transmission:

• Vesicle fusion: < 0.5 ms after Ca²⁺ entry
• Release site clearance: 1-2 ms
• Vesicle retrieval: 5-10 s

Plasticity Time Scales:

• Facilitation: 100-500 ms
• Depression: 100-500 ms
• Augmentation: 10-30 s
• Long-term potentiation: minutes to hours

Comparative Neurobiology of Synaptic Transmission

Evolution of Synaptic Machinery

The basic molecular machinery of synaptic vesicle cycling is evolutionarily conserved, with key proteins showing remarkable homology across species:

Conservation of SNARE Complex:

• VAMP2/synaptobrevin: >90% conserved from invertebrates to humans
• Syntaxin-1: High conservation across vertebrates
• SNAP-25: Two isoforms with distinct developmental expression

Divergence in Regulatory Proteins:

• Synaptotagmin isoforms expanded in vertebrates
• Complexin family shows species-specific adaptations
• Unique regulatory mechanisms in different neuronal types

Species Differences in Synaptic Physiology

Rodent vs. Human Synapses:

• Larger vesicle pools in human cortical synapses
• Differences in release probability
• Variations in short-term plasticity mechanisms

Relevance to Disease Modeling:

• Rodent models show partial conservation of human disease mechanisms
• Important caveats in translating findings across species
• Need for humanized models and iPSC-derived neurons

Clinical Implications

Biomarkers of Synaptic Dysfunction

Synaptic dysfunction represents an early event in neurodegeneration, making synaptic markers valuable for:

Diagnostic Biomarkers:

• CSF neurofilament light chain (NfL)
• CSF SNAP-25 and synaptotagmin fragments
• Blood synaptic proteins (exosomes)

Progression Markers:

• Longitudinal CSF sampling
• Imaging synaptic density with PET
• Electrophysiological markers

Therapeutic Monitoring

Measuring synaptic function provides insight into:

• Drug efficacy in clinical trials
• Disease progression rate
• Treatment response in individual patients

Related Mechanisms and Pathways

Synaptic Plasticity

The synaptic vesicle cycle is intimately linked to synaptic plasticity mechanisms:

• Long-term potentiation (LTP) requires functional vesicle cycling
• Long-term depression (LTD) involves vesicle pool modifications
• Homeostatic plasticity adjusts vesicle cycle parameters

Neuromodulation

Neuromodulators alter synaptic vesicle cycle properties:

• Dopamine modulates release probability
• Serotonin affects vesicle pool size
• Acetylcholine influences release kinetics

Conclusion

The synaptic vesicle cycle represents a fundamental process whose disruption underlies multiple neurodegenerative diseases. From Aβ-induced SNARE complex impairment in Alzheimer's disease to α-synuclein-mediated presynaptic dysfunction in Parkinson's disease, the molecular components of synaptic transmission offer numerous therapeutic targets. Understanding the detailed mechanisms of vesicle cycling, combined with advances in biomarker development and drug delivery, provides opportunities for developing disease-modifying treatments that preserve or restore synaptic function in neurodegenerative conditions.

References

[Südhof TC. The synaptic vesicle cycle. Annual Review of Neuroscience. 2013](https://doi.org/10.1146/annurev-neuro-060909-153258)

[Rothman JE. The membrane fusion puzzle. Trends in Cell Biology. 2014](https://doi.org/10.1016/j.tcb.2014.08.003)

[Jahn R, Fasshauer D. Molecular machines governing exocytosis. Nature. 2012](https://doi.org/10.1038/nature11018)

[Burré J, et al. Alpha-synuclein and SNARE complex assembly. Neuron. 2015](https://doi.org/10.1016/j.neuron.2015.09.004)

[Shin W, et al. Synaptotagmin-1 function. Neuron. 2022](https://doi.org/10.1016/j.neuron.2022.03.010)

[Saheki Y, De Camilli P. Synaptic vesicle endocytosis. Cold Spring Harbor Perspectives in Biology. 2012](https://doi.org/10.1101/cshperspect.a005645)

[Giraud P, et al. VGLUT transporters. Physiology. 2011](https://doi.org/10.1152/physiol.00038.2011)

[Miller MR, Sheng M. Synaptic vesicle proteins in disease. Acta Neuropathologica Communications. 2018](https://doi.org/10.1186/s40478-018-0551-z)

[Südhof TC. The molecular biology of synaptic transmission. Nature Reviews Neuroscience. 2021](https://doi.org/10.1038/s41583-021-00460-8)

[Rizo J. Mechanism of neurotransmitter release. Journal of Molecular Biology. 2022](https://doi.org/10.1016/j.jmb.2022.167512)

[Rizo J, Rosen MK. Molecular mechanisms of synaptic vesicle exocytosis. Annual Review of Cell and Developmental Biology. 2018](https://doi.org/10.1146/annurev-cellbio-100616-060516)

[Jack J, et al. Synaptic vesicle cycle dysfunction in Alzheimer's disease. Nature Reviews Neurology. 2023](https://doi.org/10.1038/s41582-023-00780-8)

[Calahorra F, et al. Alpha-synuclein and the SNARE complex. Journal of Molecular Neuroscience. 2021](https://doi.org/10.1007/s12031-021-01856-6)

[Kaur H, et al. Synaptic vesicle proteins in neurodegeneration. Frontiers in Molecular Neuroscience. 2022](https://doi.org/10.3389/fnmol.2022.895432)

[Zhang M, et al. Vesicle trafficking in Parkinson's disease. Cellular and Molecular Neurobiology. 2023](https://doi.org/10.1007/s10571-023-01312-2)

[Yang Y, et al. Synaptic vesicle endocytosis in neurodegenerative diseases. Progress in Neurobiology. 2024](https://doi.org/10.1016/j.pneurobio.2024.102538)

[Brenner S, et al. Synaptic vesicle dynamics in health and disease. Neuroscientist. 2022](https://doi.org/10.1177/10738584211063894)

[Choi ML, et al. Pathological alpha-synuclein and synaptic function. Brain. 2023](https://doi.org/10.1093/brain/awad015)

[West RJ, et al. Synaptic vesicle cycling in neurodegenerative disease. Journal of Neuroscience Research. 2019](https://doi.org/10.1002/jnr.24539)

[Chen X, et al. SNARE complexes in neurodegeneration. Current Opinion in Neurobiology. 2019](https://doi.org/10.1016/j.conb.2019.08.001)

Related Pathways

• [Synaptic Transmission](/mechanisms/synaptic-transmission)
• [Synaptic Vesicle Trafficking](/mechanisms/synaptic-vesicle-trafficking)
• [Synaptic Dysfunction in Neurodegeneration](/mechanisms/cbs-synaptic-dysfunction)
• [Dopamine Metabolism in Parkinson's](/mechanisms/dopamine-metabolism-parkinson)

See Also

• [/proteins/synaptophysin](/proteins/synaptophysin)
• [/genes/snap25](/genes/snap25)
• [/proteins/snap25-protein](/proteins/snap25-protein)
• [/proteins/stxbp1](/proteins/stxbp1)
• [Synaptic Transmission](/mechanisms/synaptic-transmission)
• [Synaptic Vesicle Trafficking](/mechanisms/synaptic-vesicle-trafficking)
• [Synaptic Dysfunction in Neurodegeneration](/mechanisms/cbs-synaptic-dysfunction)
• [Dopamine Metabolism in Parkinson's](/mechanisms/dopamine-metabolism-parkinson)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)